Teva Pharmaceutical Industries Ltd
PO Box 3190
5 Basel Street
Petach Tikva 49131, Israel
Phone: +972 (3) 926 7267
Fax: +972 (3) 923 4050
Email: info@teva.co.il
Website: http://www.tevapharm.com
Contact:
Board of Directors
Dr Phillip Frost, Chairman, Board of Directors Dr Phillip Frost
Prof Moshe Many, Vice Chairman, Board of Directors Prof Moshe Many
Roger Abravanel, Director, Board of Directors Roger Abravanel
Abraham Cohen, Director, Board of Directors Abraham Cohen
Amir Elstein, Director, Board of Directors Amir Elstein
Chaim Hurvitz, Director, Board of Directors Chaim Hurvitz
Prof Elon Kohlberg, Director, Board of Directors Prof Elon Kohlberg
Prof Roger Kornberg, Director, Board of Directors Prof Roger Kornberg
Prof Richard Alan Lerner, Director, Board of Directors Prof Richard Alan Lerner
Joseph Nitzani, Director, Board of Directors Joseph Nitzani
Prof Yitzhak Peterburg, Director, Board of Directors Prof Yitzhak Peterburg
Dan Propper, Director, Board of Directors Dan Propper
Prof Dafna Schwartz, Director, Board of Directors Prof Dafna Schwartz
Ory Slonim, Director, Board of Directors Ory Slonim
Dan Suesskind, Director, Board of Directors Dan Suesskind
Erez Vigodman, Director, Board of Directors Erez Vigodman
Management
Isaac Abravanel, Group Executive Vice President Human Resources and Chief Integration Officer, Management Isaac Abravanel
Dr Carlo De Notaristefani, President and Chief Executive Officer, Global Operations, Management Dr Carlo De Notaristefani
Eyal Desheh, Group Executive Vice President, Chief Financial Officer, Management Eyal Desheh
Richard Egosi, Group Executive Vice President, Chief Legal Officer and Company Secretary, Management Richard Egosi
Ron Grupel, Chief Internal Auditor, Management Ron Grupel
Dr Michael Hayden, President of Global R 7110 (Israel)
Founded: 1944.
Principal Activities: Development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients.
Mergers and Acquisitions: In 2008, the Company completed the acquisition of CoGenesys Inc, USA, Bentley Pharmaceuticals Inc, USA, and Barr Pharmaceuticals Inc., USA. In August 2010, the Company acquired the Merckle ratiopharm Group. In January 2011, the Company acquired Laboratoire Théramex and Corporación Infarmasa. In July 2011, the Company acquired Taiyo Pharaceutical Industry Co Ltd, Japan. In October 2011, the Company acquired Cephalon Inc, USA.
Trade Names: Azilect (R), Copaxone (R), Amrix (R), Fentora (R), Provigil (R), Nuvigil (R), Treanda (R).
Subsidiary Companies: Cephalon Inc (100%) (USA); CT Arzneimittel GmbH (100%) (Germany); Ivax Argentina S.A. (100%) (Argentina); Laboratoire Théramex SAM (100%) (Monaco); Laboratorio Chile S.A. (99.60%) (Chile); Lemery Desarrollo y Control SA (100%) (Mexico); Pharmachemie Holding BV (100%) (Netherlands); PLIVA HRVATSKA d.o.o. (100%) (Croatia); ratiopharm GmbH Taisho Pharmaceutical Industries Ltd (100%) (Japan); Taiyo Pharmaceutical Industry Co Ltd (100%) (Japan); Teva API BV (100%) (Netherlands); Teva API Inc (100%) (USA); Teva Canada Ltd (100%) (Canada); Teva Czech Industries s.r.o. (100%) (Czech Republic); TEVA Gyógyszergyár Zrt (100%) (Hungary); Teva Italia Srl (100%) (Italy); Teva Ltd (100%) (Russia); TEVA Magyarország Gyógyszerforgalmazó Zrt (100%) (Hungary); Teva Pharma SL (100%) (Spain); Teva Pharmaceuticals Europe BV (100%) (Netherlands); Teva Pharmaceuticals Polska Sp zoo (100%) (Poland); Teva Pharmaceuticals USA Inc (100%) (USA); Teva Santé SAS (100%) (France); Teva UK Ltd (100%) (UK).
Latest Sales turnover figure converted to USD: $18,312,000,000.